Clinical Trial

A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration

Completed Phase 1
View on ClinicalTrials.gov →
Summary
The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD). The main question it aims to answer is: Is PST-611-CT1 safe for participants? Participants will: * Receive a single dose of PST-611 * Will be followed up for a total of 16 weeks following PST-611 administration
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-09.
Status change: Not Yet Recruiting → Completed 2026-07-10
Trial Details
NCT Number NCT07024732
Lead Sponsor Eyevensys
Conditions Dry Age Related Macular Degeneration
Enrollment 8 participants
Start Date 2025-06-23
Primary Completion 2026-04-07 (estimated)
Study Completion 2026-04-07 (estimated)
Updated on ClinicalTrials.gov 2026-07-13